Thursday 7 May, 2026
Introductions: Approximately 15-20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2), a molecular subtype associated with poor…
Read morePoster: Clinical Applications
DOES THEORETICAL TARGET ATTAINMENT REFLECT REAL-WORLD TARGET ACHIEVEMENT? AN EVALUATION IN INTENSIVE CARE UNIT PATIENTS RECEIVING PIPERACILLIN AS CONTINUOUS INFUSION
Thursday 7 May, 2026
Introduction: Model-informed precision dosing (MIPD) aims to individualise antimicrobial therapy using pharmacokinetic models. These models need to be evaluated prior…
Read morePhysiologically Based Pharmacokinetic Modeling of Rilpivirine to Support Trimester-Specific Dose Optimization in Pregnant Women Living With HIV
Thursday 7 May, 2026
Objectives: Rilpivirine (RPV) systemic exposure decreases by approximately 30-50% during the second and third trimesters of pregnancy, raising concerns about…
Read moreExposure Comparison of Standard Versus Alternate Hydroxyurea Dosing in Ugandan Children with Sickle Cell Disease: A Non-Compartmental Pharmacokinetic Analysis
Thursday 7 May, 2026
Background Hydroxyurea (HU) is the standard disease-modifying therapy for sickle cell disease (SCD), improving survival and reducing vaso-occlusive complications through…
Read moreTEZEPELUMAB POPULATION PHARMACOKINETICS SUPPORTS PAEDIATRIC EXTRAPOLATION IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (CRSwNP)
Thursday 7 May, 2026
Introduction/Objectives: Tezepelumab (210 mg subcutaneously [SC] every 4 weeks [Q4W]) is approved in several markets worldwide as an add-on maintenance…
Read moreDOSE SELECTION BY A MODEL-INFORMED DRUG DEVELOPMENT (MIDD) APPROACH FOR NAPORAFENIB AND TRAMETINIB COMBINATION IN PATIENTS WITH MELANOMA
Thursday 7 May, 2026
Introduction: Naporafenib is a potent and selective adenosine triphosphate (ATP)-competitive inhibitor of the wild-type CRAF and BRAF protein kinases and…
Read moreAdherence to Ribociclib Treatment: Insights from Population Pharmacokinetic Simulations and Plasma Concentration Measurements
Thursday 7 May, 2026
Objectives: Ribociclib, a cyclin-dependent kinase 4/6 inhibitor, is an established therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative…
Read moreCharacterization of real-world pembrolizumab population pharmacokinetics in cancer patients: towards identification of non-responders using change in clearance as efficacy biomarker and individualization of the dosing interval
Thursday 7 May, 2026
Background: The approved dose of pembrolizumab was established in phase I-III clinical studies with 2 mg/kg every three weeks (Q3W)…
Read moreFemale contraceptive cover duration for miltefosine-containing regimens for the treatment of leishmaniasis
Thursday 7 May, 2026
Introduction: Miltefosine is the only approved oral therapy for leishmaniasis and remains a key treatment for visceral leishmaniasis (VL), post-kala-azar…
Read moreModel-informed pediatric drug development for clevidipine
Thursday 7 May, 2026
Introduction: Clevidipine is an intravenous L‑type calcium channel blocker administered intravenously (IV) for the rapid reduction of blood pressure (BP)…
Read more